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ABSTRACT
Objectives Spontaneous pneumothorax is a common
pathology. International guidelines suggest pleurodesis
for non-resolving air leak or recurrence prevention at
second occurrence. This study comprehensively reviews
the existing literature regarding chemical pleurodesis
efﬁcacy.
Design We systematically reviewed the literature to
identify relevant randomised controlled trials (RCTs),
case–control studies and case series. We described the
ﬁndings of these studies and tabulated relative
recurrence rates or ORs (in studies with control groups).
Meta-analysis was not performed due to substantial
clinical heterogeneity.
Results Of 560 abstracts identiﬁed by our search
strategy, 50 were included in our systematic review
following screening. Recurrence rates in patients with
chest tube drainage only were between 26.1% and
50.1%. Thoracoscopic talc poudrage (four studies
(n=249)) provided recurrence rates of between 2.5%
and 10.2% with the only RCT suggesting an OR of 0.10
compared with drainage alone. In comparison, talc
administration during video-assisted thoracic surgery
(VATS) from eight studies (n=2324) recurrence was
between 0.0% and 3.2%, but the RCT did not
demonstrate a signiﬁcant difference compared with bleb/
bullectomy alone. Minocycline appears similarly effective
post-VATS (recurrence rates 0.0–2.9%). Prolonged air
leak and recurrence prevention using tetracycline via
chest drain (n=726) is likely to provide recurrence rates
between 13.0% and 33.3% and autologous blood
patch pleurodesis (n=270) between 15.6% and 18.2%.
Conclusions Chemical pleurodesis postsurgical
treatment or via thoracoscopy appears to be most
effective. Evidence for deﬁnitive success rates of each
agent is limited by the small number of randomised
trials or other comparative studies.
INTRODUCTION
Pneumothorax, air in the pleural space, is a
common pathology. Primary spontaneous pneumo-
thorax (PSP) refers to patients with no underlying
lung disease, while those with established lung
pathology are classiﬁed as secondary spontaneous
pneumothorax (SSP). The incidence of spontan-
eous pneumothoraces based on populations in the
USA1 and Sweden2 is reported as 18–24 per
100 000 cases per annum for men and 1.2–6 per
100 000 for women. PSP has a reported incidence
of 7.4–18 cases (age-adjusted incidence) and 1.2–6
cases per 100 000 population per year for males
and females, respectively.1 2 UK data on hospital
admission rates (for PSP and SSP combined) dem-
onstrate an incidence of 16.7 cases per 100 000 for
men and 5.8 cases per 100 000 for women, with
corresponding mortality rates of 1.26 per million
and 0.62 per million per annum.3 More recent data
from France have demonstrated a similar rate of
22.7 cases per 100 000 population.4
Recurrence rates for spontaneous pneumothorax
(SP) are quoted as approximately 30%, with indi-
vidual studies reporting a recurrence rate of
between 17% and 49%.5–12 Initial treatment regi-
mens and strategies for recurrence prevention
remain controversial. Recurrence prevention
involves an attempt at pleurodesis (permanent
apposition of the visceral and parietal pleura to seal
the pleural space), which can be chemical (or
‘medical’) using an agent introduced into the
pleural cavity or surgical by apical pleurectomy or
pleural abrasion. International guidelines currently
recommend pleurodesis for non-resolving pneu-
mothoraces acutely or electively to prevent recur-
rence after a second occurrence of pneumothorax.
However, guidelines do not specify the optimal
pleurodesis approach or agent for chemical pleur-
odesis.13–15
Key messages
What is the key question?
▸ How effective are chemical pleurodesis agents
at recurrence prevention in spontaneous
pneumothorax?
What is the bottom line?
▸ Talc poudrage at thoracoscopy and talc or
minocycline pleurodesis as an adjunct to
surgery provide low recurrence rates. Less
invasive options include pleurodesis using
tetracycline or ‘blood patch’ via chest drain.
Why read on?
▸ This review is the ﬁrst to systematically assess
the evidence for pleurodesis efﬁcacy in
recurrence prevention for all chemical
pleurodesis agents in cases of spontaneous
pneumothorax in both ‘medical’ pleurodesis (ie,
no intervention on the lung) and as an adjunct
to surgical procedures.
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For PSP, the American College of Chest Physicians (ACCP)
Delphi consensus statement13 recommends surgical pleurodesis
via thoracoscopy (including bullectomy) for ongoing air leak
(>4 days) or recurrence prevention at second occurrence. In this
statement, there was no consensus on the utility of additional
talc poudrage at surgical procedure for patients with PSP.
Chemical pleurodesis via a chest drain was thought to be accept-
able for patients in whom surgery was contraindicated or
patients who refused an operative procedure. The statement
recommends doxycycline or talc as the preferred agent in cases
where chemical pleurodesis is conducted.13 For SSP, this state-
ment suggests intervention to prevent pneumothorax recurrence
at ﬁrst occurrence (in contrast to PSP), with the surgical
approach as ﬁrst choice and chemical pleurodesis as an option
for the high-risk patient or those declining surgery. The ACCP
guidance was published in 2001, and therefore may no longer
be up to date.
The British Thoracic Society (BTS, 2010)14 and the Belgian
Society of Pulmonology (BSP, 2005)15 guidelines for PSP and
SSP both recommend surgical pleurodesis for ongoing air leak
acutely and recurrence prevention at second occurrence. They
state that “with the advent of VATS for pneumothorax repair
and recurrence prevention, the use of surgical chemical pleurod-
esis has declined signiﬁcantly”.14 Medical chemical pleurodesis
is recommended in patients unwilling or unable to undergo
surgery, and is therefore more likely to be applicable to patients
with SSP. The BTS makes reference to tetracycline as the previ-
ous ﬁrst-line agent for PSP and SSP, but with decline in usage
through difﬁculties in supply in favour of graded talc, with
passing mention of minocycline and doxycycline efﬁcacy in
animal models.14 The BSP does not comment on pleurodesis
agent.
This study aimed to systematically review the existing litera-
ture regarding the efﬁcacy of chemical pleurodesis for recur-
rence prevention in pneumothorax.
METHODS
Eligibility criteria
We systematically reviewed the literature to identify relevant
randomised controlled trials (RCTs), case–control studies and
case series (without comparator groups) of ≥10 cases. Case
series were speciﬁcally included because the authors were aware
of a dearth of trials data in this area.
Studies were considered eligible for inclusion with the follow-
ing criteria: adult patients (≥18 years old) with spontaneous
(primary and secondary) pneumothorax, undergoing pleurod-
esis at ﬁrst occurrence or subsequent recurrence, or for the
treatment of persistent air leak, by instillation via chest tube or
in addition to surgical procedure; interventions consisting of
chemical pleurodesis with any agent. Comparators included
were any of chest tube drainage alone (no pleurodesis), other
pleurodesis agent and surgical procedures (eg, mechanical abra-
sion, bleb/bullectomy, pleurectomy). The outcome was pneumo-
thorax recurrence rate (ideally, after at least 1 year of
follow-up).
Exclusions consisted of the following: animal or paediatric
studies, non-primary studies (ie, letters, editorials and review
articles), pleurodesis for malignant pleural effusion, surgical
pleurodesis only (with no sclerosant inserted), pleurodesis for
postoperative air leak, insufﬁcient data on agent or technique
used, inadequate follow-up period (ie, <3 months) and case
series with <10 cases.
Papers were also excluded if the authors were unable to
obtain a translation (if not published in English) or unable to
obtain the paper online or via our hosts’ extensive library access
collections.
Search strategy
Literature searches of multiple databases (including PubMed,
Embase, Medline, Web of Science, Cochrane Library) were
performed up to and including June 2016. Results were not
restricted by year of publication. Combinations of search terms
were used and adapted for each database as appropriate, in-
cluding “pleurodesis”, “spontaneous”, “pneumothor*”, “chem-
ical”, “talc”, “tetracycline”, “minocycline”, “iodopovidine” and
“blood”. In addition to electronic database searches, reference
lists, relevant textbooks and review articles were hand-searched
and back-referenced (ie, reference lists of review articles exam-
ined for additional studies not appearing in initial searches).
Abstracts were independently reviewed for relevance by two
authors (RJH and AY). Any discrepancies were resolved by dis-
cussion (with JPC and IP) with a low threshold for review of
the full article. Relevant full journal articles were subsequently
assessed again for eligibility.
Data extraction
Data were extracted from the full articles separately by two
authors using a prespeciﬁed extraction form (Microsoft Excel
2010, Microsoft, USA). Extracted information included lead
author, year, geographical area, nature of pneumothorax
(primary or secondary, where available), number of participants,
intervention agent(s), control/comparator measures, recurrence
rate for each arm, follow-up timescale (mean or median when
described), study type and quality. In those with mixed popula-
tions (eg, including patients with pleural effusions or post-
operative air leak), only data pertaining to SP were extracted.
Where available, data on number of episodes of pneumothorax
(rather than number of patients) were extracted. Early pleurod-
esis failures that required further procedure or surgical referral
were included in the calculated recurrences rates.
Quality and risk of bias assessment
Risk of bias of the included RCTs was assessed using the
Cochrane Risk of Bias tool.16 This tool addresses seven
domains: sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting and
‘other issues’. We did not formally assess risk of bias in case–
control studies or case series.
Data analysis
Given the considerable heterogeneity in study design, pleurod-
esis agents, control groups and outcomes across identiﬁed
studies, formal data synthesis via meta-analysis was not con-
ducted as any results would not be clinically meaningful. ORs
with 95% CIs were calculated where possible as a measure of
the effectiveness in reducing pneumothorax recurrence relative
to a control. For studies with no comparison group, we display
simply estimates of the pneumothorax recurrence rate in the
single arm, with a 95% CI (calculated on the log scale). When
zero recurrences occurred, we approximated the upper limit of
the CI for recurrence rate by 3/n16 (Section 16.9.4) and applied
the standard approximation of adding 0.5 to all cell counts
before calculating ORs and their CIs16 (Section 16.9.2).
RESULTS
After deduplication of search results, 560 abstracts were reviewed
(see ﬁgure 1). In total, 468 were excluded as not eligible for our
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review at this stage (case reports, reviews, surgical series or
description of practice, animal models, paediatric cases, pleurod-
esis for pleural effusions only, duplicate data or basic science arti-
cles) and we were unfortunately unable to obtain full-text copies
of 13 papers published prior to 1995 (in foreign language). Of
the remaining 92 potentially eligible papers, an additional 42
studies were identiﬁed as not being eligible for data extraction
(20 within inadequate data or no long-term follow-up data, 6
reviews, 6 with <10 cases, 4 were duplicate data from other pub-
lications, 4 conference posters or abstracts only and 2 only
related to pleural effusion management) when full texts were
screened. Hence, 50 relevant studies were identiﬁed. We sum-
marise results from 50 studies.
These 50 studies varied in size, quality and study design: 9
RCTs, 10 prospective case series (3 with non-randomised com-
parator groups) and 31 retrospective case series (10 with non-
randomised comparator groups). The indication for pleurodesis
varied; 16 (32%) studies stated an indication of pneumothorax
recurrence or ongoing air leak, 7 (14%) enrolled only those at
ﬁrst occurrence, 6 (12%) assessed patients with ongoing air
leak, 5 (10%) studied recurrent pneumothorax only and 3
studies (6%) enrolled a mixture of ﬁrst occurrence, recurrent
pneumothorax and ongoing leak or haemothorax. The
remaining 13 studies (26%) did not specify the indication for
recurrence prevention precisely enough to categorise this
further.
Assessment of bias of the RCTs showed a low risk of report-
ing, detection or attrition bias as the outcomes of pneumo-
thorax recurrence were well reported and the loss to follow-up
was low. The randomisation process was generally well
described and adequate, with the exception of some of the
older studies that did not describe the process6 7 and a more
recent study that appeared to be alternating treatment arms
based upon trial number.17 None of the studies were blinded,
some providing explanation of why this was not attempted: dif-
ﬁculties of matching colour of agent or that the expected pain
associated with minocycline instillation would be likely to
unmask the blinding.
Talc
Twenty-four studies used talc as a chemical pleurodesis agent.
Twelve assessed the efﬁcacy of talc poudrage for the treatment
of PSP: four in which talc poudrage was performed at medical
thoracoscopy with no associated intervention on the lung
(table 1) and eight in which talc poudrage was administered
post-video-assisted thoracoscopic surgery (VATS) with bleb elec-
trocoagulation, bleb resection or apical bullectomy (table 2).
Of the four studies in which talc poudrage was performed
without intervention on the lung (table 1), only one was an
RCT. It demonstrated a lower recurrence rate among those
receiving talc poudrage compared with those treated with drain-
age alone (talc 5.1% vs drainage 34.0%, OR 0.10, 95% CI 0.03
Figure 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) ﬂow diagram of study selection.
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to 0.38).18 A case series study with a (non-randomised) control
arm provided similar estimates: talc 2.6% versus drainage
26.1%, OR 0.08 (95% CI 0.01 to 0.69).19 Two case series,
without comparators, estimated 10.2% recurrence in patients
presenting with recurrent PSP or ongoing air leak (including
early failures),20 and 9.5% in combination of ﬁrst episode
(62%) and recurrent (38%) PSPs.21 All four studies had
follow-up periods of at least 24 months (table 1).
In the eight surgical studies evaluating talc poudrage for PSP
post-VATS with bleb electrocoagulation, bleb resection or apical
bullectomy, the follow-up period was variable from 10 to
62 months (table 2). There was only one RCT, which was
carried out in 141 patients undergoing VATS with bleb resection
or electrocoagulation. The recurrence rate among patients
receiving talc and dextrose was 2.4% compared with 6.0% in
the control arm of surgery only. However, the CI for the OR
was very wide, indicating that we cannot be conﬁdent about this
ﬁnding: OR 0.38 (95% CI 0.04 to 3.82).22 Further, similar
results were also seen by simply introducing dextrose without
talc.22 Observed recurrence rates across the other seven surgical
studies were between 0.0% and 3.2%.23–29 Only two of these
had (non-randomised) comparator groups,26 29 one of which
provided statistical evidence for a reduced recurrence rate in
those receiving talc compared with pleural abrasion: talc 1.5%
versus pleural abrasion 4.0%, OR 0.38 (95% CI 0.15 to
0.97).26
Indications for surgical intervention in these studies were
recurrent PSP or ongoing air leak,24 25 28 including ﬁrst presen-
tation in two studies,23 29 one solely treating ﬁrst occurrence27
and two in which this aspect was not speciﬁed.22 26 The surgical
procedures undertaken varied both within and across the
studies. Some studies stated that bleb/apical electrocoagulation
or resection was only performed if visible abnormalities were
seen,23 25 28 29 whereas others performed the procedure in all
cases.22 24 26 27
The remaining 12 studies used talc to treat both patients with
PSP and SSP (table 3). One RCT estimated a reduction in recur-
rence rates by performing talc pleurodesis via chest drain com-
pared with drainage alone, OR 0.16 (95% CI 0.03 to 0.85).6
Two small studies insufﬂated talc under local anaesthetic and
reported 0% recurrence in 24 patients30 and 20 patients,31
respectively. However, four larger series including 521 patients
undergoing talc poudrage at thoracoscopy found recurrence
rates of 5.6–16.1% (including early failures).32–35 One study
comparing talc to autologous blood pleurodesis found lower
recurrence in the talc group (OR 0.48) but wide CIs (0.10 to
2.24).36 A retrospective case series of 122 patients using talc
pleurodesis via chest drain found a similar recurrence rate of
13.3%.37 A further three retrospective surgical studies, including
317 patients undergoing VATS bullectomy and talc poudrage
for PSP and SSP, found recurrence rates of 1.1–4.5%.38–40 The
(non-randomised) comparator groups of the two studies
(n=312) found the recurrence rate for talc via chest drain for
SSP to be 2.9%38 and 30.8%.40 Although the difference in the
latter study was statistically signiﬁcant, the two patient groups
were very different: patients receiving talc via chest drain were
those not deemed ﬁt for VATS.40
Tetracycline
Eleven studies evaluated the efﬁcacy of tetracycline pleurodesis
for SP via chest drains or thoracoscopy without intervention on
the lung (table 4). These were of variable quality including both
PSP and SSP but comprised three RCTs including a total of 366
patients. Two RCTs, from 1990 and 1989, randomised patients
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Table 2 Efficacy of talc pleurodesis for primary spontaneous pneumothorax: post surgery (intervention on lung)
Study author Year Study design
Total number
of cases Intervention (n) Cointervention
Intervention
recurrence rate
(95% CI)
Control/reference
arm (n)?
Control/reference
recurrence rate
(95% CI)
Follow-up
period
(months)
OR (vs control/
reference)
(95% CI)
RCT
Chung22 2008 RCT (3 arms) 141 Talc and dextrose
(42)
VATS+bleb resection or
electrocoagulation
2.4% (0.3% to 17.3%) Drainage only (50) 6.0% (1.9% to 19.3%) 24MN, 20MN 0.38 (0.04 to 3.82)
Dextrose only
(49)
“ 2.0% (0.3% to 14.8%) 18MN 0.33 (0.03 to 3.25)
Prospective series
Ramos-Izquierdo23 2010 Prospective
series
133 Talc poudrage
(133)
VATS±bleb
electrocoagulation
3.2% (1.2% to 8.7%) – – 36MN –
Dubois24 2010 Prospective
series
72 Talc poudrage
(72)
VATS+apical bullectomy 0% (0.0% to 4.2%) – – 12MN –
Retrospective case series (with comparator group)
Moreno-Merino26 2012 Retrospective
case series
787 Talc poudrage
(388)
VATS+bullectomy 1.5%* (0.7% to 3.5%) Pleural abrasion†
(399)
4.0%* (2.4% to 6.6%) Unclear 0.38 (0.15 to 0.97)
Janssen29 1994 Retrospective
case series
44 Talc poudrage
(21)
VATS±bleb resection or
electrocoagulation‡
0% (0.0% to 14.3%) VATS-bullectomy
(23)‡
8.7% (2.0% to 37.1%) >18 0.20 (0.01 to 4.42)
Retrospective case series (no comparator group)
Cardillo25 2006 Retrospective
case series
861 Talc poudrage
(861)
VATS±bullectomy 1.7%§ (1.0% to 3.0%) – – 53MN –
Margolis27 2003 Retrospective
case series
156 Talc poudrage
(156)
VATS+bleb resection 0% (0.0% to 1.9%) – – 62MD –
Mármol Cazas28 2011 Retrospective
case series
130 Talc poudrage
(130)
VATS±bullectomy 3.1% (1.1% to 8.3%) – – 10MN –
*Includes early treatment failures requiring reintervention.
†Historical comparison.
‡Thoracoscopic talc poudrage was performed in patients with normal pleura or bullae <2 cm diameter, bullectomy was performed in those with bullae >2 cm.
§Excluded 56 lost to follow-up.
MD, median; MN, mean; RCT, randomised controlled trial; VATS, video-assisted thoracic surgery.
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Table 3 Efficacy of talc pleurodesis on spontaneous pneumothorax (PSP and SSP): medically and surgically treated
Study
author Year Study design
Total
number
of cases
PSP or
SSP? (n) Intervention (n)
Intervention
recurrence rate
(95% CI)
Control/reference
arm (n)?
Control/reference
recurrence rate
(95% CI)
Follow-up
period
(months)
OR (vs control/
reference)
(95% CI)
RCTs—medical
Almind6 1989 RCT* 96* PSP (71)
SSP (25)*
Talc via chest drain (29) 8.3% (2.0% to 35.4%) Drainage only (34) 36.0% (15.9% to 81.5%) 55MN 0.16 (0.03 to 0.85)
Prospective series—medical
Noppen32 1997 Prospective case
series
54 PSP (31)
SSP (23)
Talc at thoracoscopy (54)
±bleb electrocoagulation
7.4% (2.7% to 20.5%) – – 18MN –
Milanez33 1994 Prospective case
series
18 PSP (15)
SSP (3)
Talc at thoracoscopy (18) 5.6% (0.7% to 41.7%) – – 38.5MN –
Retrospective case series—medical (with comparator group)
Aihara36 2011 Retrospective
case series
36 PSP (0)
SSP (36)
Talc via chest drain (14) 24.1% (6.0% to 76.8%) Blood (22) 36.4% (15.3% to 86.7%) 15MN 0.48 (0.10 to 2.24)
Retrospective case series—medical (no comparator group)
Van de
Brekel34
1993 Retrospective
case series
356† Unclear Talc at thoracoscopy (356) 12.1% (8.8% to 16.6%) † † 12–240 –
Weissberg37 1993 Retrospective
case series
122 Unclear Talc via chest drain (122) 13.3% (7.7% to 22.9%) – – Unclear –
Tschopp35 1997 Retrospective
case series
93 PSP (65)
SSP (28)
Talc at thoracoscopy (93) 16.1% (9.3% to 28.0%) – – 60 –
Nandi30 1980 Retrospective
case series
24 PSP (0)
SSP (24)
Talc via chest drain (24) 0% (0.0% to 12.5%) – – 2–24 –
Pletinckx31 2005 Retrospective
case series
20 PSP (5)
SSP (15)
Talc at thoracoscopy (54)
±bleb resection
0% (0.0% to 15.0%) – – –
Retrospective case series—surgical (with comparator group)
Shaikhrezai38 1984 Retrospective
case series
519 PSP (444)
SSP (75)
VATS+bullectomy+talc
poudrage (246)
1.2% (0.4% to 3.8%) VATS+bullectomy
+abrasion (273)
2.9% (1.5% to 5.9%) 73MD 0.41 (0.11 to 1.56)
Kim40 2011 Retrospective
case series
61 PSP (0)
SSP (61)
VATS+bullectomy+talc (22) 4.5% (0.6% to 33.8%) Drainage+talc via
drain (39)
30.8% (15.6% to 60.7%) Unclear 0.11 (0.01 to 0.89)
Retrospective case series—surgical (no comparator group)
de Campos39 2001 Retrospective
case series
49 Unclear VATS+bullectomy+talc (49) 2.0% (0.3% to 14.8%) – – 24–60 –
Follow-up range shown if no average given.
*RCT had three arms (total numbers include tetracycline arm, n=33).
†Thoracotomy and bullectomy were performed in those with bullae >2 cm at thoracoscopy—not included in analysis.
MD, median; MN, mean; PSP, primary spontaneous pneumothorax; RCT, randomised controlled trial; SSP, secondary spontaneous pneumothorax; VATS, video-assisted thoracic surgery.
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Table 4 Efficacy of tetracycline pleurodesis for spontaneous pneumothorax (no intervention on lung)
Study author Year Study design
Total
number of
cases
PSP or
SSP? (n) Intervention (n)
Intervention recurrence
rate
(95% CI)
Control/
reference arm
(n)?
Control/reference
recurrence rate
(95% CI)
Follow-up period
(months)
OR (vs control/
reference)
(95% CI)
RCTs—medical
Light7 1990 RCT 229 PSP (46)
SSP (183)
Tetracycline via chest
drain (113)
25.0% (16.2% to 38.0%) Drainage only
(116)
40.7% (28.0% to 58.7%) 29–34MN 0.48 (0.27 to 0.85)
Almind6 1989 RCT* 96* PSP (71)
SSP (25)*
Tetracycline via chest
drain (33)
13.0% (3.9% to 43.9%) Drainage only
(34)
36.0% (15.9% to 81.5%) 55MN 0.27 (0.06 to 1.15)
Wied41 1983 RCT 41 PSP (41) Tetracycline at
thoracoscopy (18)
0% (0.0% to 16.7%) Silver nitrate
(22)
0% (0.0% to 13.6%) 14MD –
Prospective series—medical
Alfageme42 1994 Prospective case
series
146 PSP (96)
SSP (50)
Tetracycline via chest
drain (78)
18.9%† (10.6% to 33.8%) Drainage only
(68)
35.3% (19.9% to 62.7%) 45MN 0.43 (0.19 to 0.97)
Prospective series—surgical
Waterworth47 1995 Prospective
series
32 PSP (32) VATS+bullectomy
+tetracycline (32)
9.4% (2.9% to 30.8%) – – 19MD –
Retrospective case series—medical (with comparator group)
Guo43 2005 Retrospective
case series
138 PSP (86)
SSP (52)
Tetracycline via chest
drain (45)
33.3% (17.9% to 62.0%) Drainage only
(70)
50.0% (31.3% to 79.9%) 6–69 0.50 (0.23 to 1.09)
Tanaka44 1993 Retrospective
case series
78‡ SSP (78) Tetracycline via chest
drain (32)
18.8% (7.7% to 45.6%) Drainage only
(46)
47.8% (26.8% to 85.3%) 48MN 0.25 (0.09 to 0.73)
van den
Brande45
1989 Retrospective
case series
20 PSP (20) Tetracycline and 30%
glucose via chest drain
(10)
30.0% (7.8% to 100%) Drainage only
(10)
50.0% (14.5% to 100%) 26MN (intervention)
and 18MN (control)
0.43 (0.07 to 2.68)
Retrospective case series—surgical (with comparator group)
Lee46 2008 Retrospective
case series
91 PSP (91) VATS+bullectomy
+tetracycline (27)
0.0% (0.0% to 11.1%) Drainage only
(64)
10.9% (5.0% to 24.0%) 16MN 0.14 (0.01 to 2.53)
Retrospective case series—medical (no comparator group)
Olsen64 1992 Retrospective
case series
390§ PSP (390) Tetracycline at
thoracoscopy (390)
15.6% (11.9% to 20.6%) § § 43MD –
Primrose65 1984 Retrospective
case series
19¶ Unclear Tetracycline via chest
drain (19)
47.4% (19.2% to 100%) – – Unclear –
Follow-up range shown if no average given.
*RCT had three arms (total numbers include talc arm, n=29).
†Includes eight early treatment failures.
‡Excluding patients being observed or aspirated only and those having thoracotomy.
§Thoracotomy and bullectomy were performed in those with bullae >2 cm at thoracoscopy—not included in analysis.
¶Small subgroup of patients undergoing pleurodesis.
MD, median; MN, mean; PSP, primary spontaneous pneumothorax; RCT, randomised controlled trial; SSP, secondary spontaneous pneumothorax; VATS, video-assisted thoracic surgery.
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to either tetracycline versus chest drain or drainage only.6 7
Both reported lower rates in the tetracycline arm but only one
study was statistically signiﬁcant, OR 0.48 (95% CI 0.27 to
0.85).7 The other small RCT of tetracycline versus silver nitrate
at thoracoscopy found recurrence rate of 0% in both arms.41
Four non-randomised retrospective studies of tetracycline versus
drainage alone all estimated reduced recurrence rates in the
tetracycline group. However, all but one had wide CIs crossing
the null value of 1: OR 0.50 (95% CI 0.23 to 1.09), 0.25 (95%
CI 0.09 to 0.73), 0.43 (95% CI 0.07 to 2.68) and 0.14 (95%
CI 0.01 to 2.53).42–45 It should be noted that four studies
included only patients with ﬁrst occurrence of SP,6 41 43 45 with
the remaining seven studies not specifying indication for recur-
rence prevention. One surgical study of tetracycline after VATS
bullectomy reported no recurrences (0.0%) in contrast to
10.9% in a group treated non-surgically with chest tube drain-
age alone.46 However, another older prospective surgical series
showed a recurrence rate of 9.4% with no control group.47
Blood
Five studies of blood patch pleurodesis were included in the
analysis (n=270, table 5). There were no RCTs compared with
drainage alone. Two studies prospectively enrolled patients after
SP with persistent air leak. One non-randomised study estimated
an OR of 0.47 (95% CI 0.17 to 1.32) for recurrence in patients
following autologous blood pleurodesis compared with drainage
alone (15.6% blood pleurodesis, including early failures requir-
ing surgery, vs 28.1% drainage).48
As noted in the ‘Talc’ section above, a small retrospective
comparison study of talc via chest drain versus blood patch was
inconclusive.39 Two further small retrospective series of patients
unﬁt for surgery with recurrence or persistent air leak found
long-term recurrence of 16.0%49 and 16.1%50 with no com-
parator groups.
Minocycline
Three RCTs in patients with PSP (n=498) found recurrence
rates of 0%17 and 1.9% after the instillation of minocycline
after lung re-expansion post-VATS procedure51 but 29.2% after
instillation via chest drain only (ie, medical management, no
intervention on the lung) in patients with ﬁrst presentations of
PSP52 (table 6). This RCT provided evidence of a reduction in
recurrence compared with drainage only in non-surgical patients
(minocycline 29.2% vs drainage only 49.1%, OR 0.43, 95% CI
0.24 to 0.75).52 Among surgical patients, Chen et al51 also
observed a reduced recurrence rate compared with patients
receiving saline, but the strength of statistical evidence was weak
(minocycline 1.9% vs saline 8.1%, OR 0.23, 95% CI 0.05 to
1.09). The third surgical RCT, comparing minocycline versus
mechanical abrasion, was small and inconclusive (minocycline
0.0% vs mechanical abrasion 5.0%, OR 0.18, 95% CI 0.01 to
3.89).17
There were also two retrospective non-randomised studies
with control arms. One suggested that minocycline signiﬁcantly
reduced recurrence rates with minocycline post-VATS compared
with saline (minocycline 2.9% vs 9.8% saline, OR 0.27, 95%
CI 0.09 to 0.85) in a historical comparison.53 The other com-
parative study in patients with prolonged air leak post-VATS for
SP found increased recurrence rates in the minocycline group
compared with OK-432 (estimated failure rate 36.7% minocy-
cline vs 5.3% OK-432, OR 10.42, 95% CI 1.30 to 83.5).54
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Other agents
A retrospective surgical series of 81 cases reported a recurrence
rate of 6.2% when using iodopovidone during VATS despite
only 37% undergoing bullae resection. Two small studies in
India assessed the efﬁcacy of iodopovidone via chest drain. One
randomised trial (n=35) had no recurrence in either the iodo-
povidone or talc pleurodesis arms55 and a retrospective review
of 27 cases found a recurrence rate of 7.4%.56
Two studies used silver nitrate as a chemical pleurodesis
agent: one RCT (see table 4) reported 0% recurrence after
instillation at thoracoscopy but described increased pleural ﬂuid
production and longer hospital stay than using tetracycline.41 A
retrospective surgical study (n=184, 3 years follow-up) used
silver nitrate after VATS bullectomy with a recurrence rate of
1.1%, but had no comparison group.57 A retrospective series
reviewing recurrence prevention at ﬁrst occurrence found a sig-
niﬁcant recurrence rate using gentamicin via chest drain,
although this was more efﬁcacious than drainage alone (3-year
recurrence rates 26.1% and 50.0%, respectively (OR 0.35, 95%
CI 0.12 to 1.00, with a reported p value <0.05).43 A small
study including 17 spontaneous pneumothoraces found only
one recurrence (5.9%) after administration of quinacrine.58 In a
group of 57 patients with SSP deemed too high risk for surgery
with ongoing air leak, ﬁbrin glue (diluted fourfold) was instilled
via chest drain. The long-term (60 months) recurrence rate was
10.5%.59 The addition of acromycin post-VATS bullectomy
reportedly reduced recurrence to 3.8% from 20.0%, in a non-
randomised historical comparison group, but CIs were wide
(OR 0.16, 95% CI 0.02 to 1.48), despite the authors stating a
p value <0.05.60
DISCUSSION
This is the ﬁrst study to our knowledge to systematically review
the evidence for the effectiveness of pleurodesis in recurrence
prevention for all chemical pleurodesis agents in cases of SP in
both ‘medical’ pleurodesis (ie, no intervention on the lung) and
as an adjunct to surgical procedures. Patients with postoperative
surgical air leak were speciﬁcally excluded as patients having
undergone thoracic surgery (eg, for wedge resection or lobec-
tomy) with subsequent air leak are likely to be a different popu-
lation from those with spontaneous pneumothoraces. For the
same reason, unlike previous reviews of pleurodesis efﬁcacy,
patients undergoing pleurodesis for malignant pleural effusion
recurrence prevention were excluded.
Given the considerable heterogeneity across studies in design,
outcomes and interventions, formal data synthesis via meta-
analysis was not conducted as we do not believe the results
would be clinically meaningful. Only 9 of 50 studies were
RCTs. Also, 13 of the 41 other studies (case series) provided
comparator groups but these were historical comparisons or
non-randomised comparator groups. The lack of head-to-head
comparisons limits the ability to formally compare relative
effectiveness of different agents in this review. This is in contrast
to a recent Cochrane review of pleurodesis agents in malignant
pleural effusion, in which a network meta-analysis of pleurod-
esis agents was possible with 62 RCTs identiﬁed.61
Studies in which the control arms were drainage with a chest
drain only (ie, no other agent) suggest recurrence rates of
26.1–50.1%. Talc pleurodesis would appear to be effective at
reducing recurrence for PSP when used via poudrage at thoraco-
scopy, with two studies with comparator arms giving recurrence
rates of 5.1% and 2.6% with OR 0.10 (95% CI 0.03 to 0.38) and
0.08 (95% CI 0.01 to 0.69), respectively, when comparing talc
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poudrage to drainage alone.18 19 However, more recent case series
data suggested higher recurrence rates (9.5%20 and 10.2%).21
When talc is used in patients undergoing surgical (VATS) pro-
cedures, the recurrence rate appears to be low (between 0.0%
and 3.2%) and it seems that the addition of talc contributes to a
lower recurrence compared with VATS bullectomy and either
drainage or abrasion alone. There have been no direct compari-
sons of VATS bullectomy and pleurectomy to VATS bullectomy
and talc pleurodesis. Results for talc poudrage at thoracoscopy
(without interventional on the lung) in the general SP (PSP and
SSP) appear to be between 5.6% and 16.1% in larger case series
(without comparator arms). No studies of talc slurry pleurodesis
for SP alone were found, except two studies with small com-
parator groups of 14 and 10 patients, which gave 21.4% and
0.0% recurrence rates, respectively.36 55 A previous systematic
review of talc pleurodesis of 22 studies in 1994 found an
overall success rate of 91%; however, 6 of 15 studies assessing
talc poudrage and the 4 studies assessing talc slurry were small
(≤10 patients) such that estimated rates are very imprecise.62
The majority of studies assessing the reduction in recurrence
rate by ‘medical’ pleurodesis agents via chest drain involve tetra-
cycline. The higher-quality studies (RCTs) would suggest a
recurrent rate of between 13% and 25%, which is signiﬁcantly
better than those receiving drainage only (OR 0.27, 95% CI
0.06 to 1.15, and 0.61 with 0.48, 95% CI 0.27 to 0.85).6 7
Blood patch pleurodesis for persistent air leak in those patients
not ﬁt for surgery seems to deliver a recurrence rate of around
16%.49 50 An RCT assessing the short-term efﬁcacy of autologous
blood patch pleurodesis at varying doses found that administration
of 1 or 2 mL/kg was more successful at ceasing air leak by 13 days
(both 82%) than 0.5 mL/kg or saline (27% and 9%,
respectively).63
Minocycline appears to be the agent of choice in Taiwan.
Instillation of talc via chest drain once the lung has re-expanded
post-VATS bullectomy results in a low recurrence rate.17 51 53
Minocycline via chest drain without surgical intervention in
patients with ﬁrst presentation of PSP also seems to provide a
signiﬁcant reduction in recurrence,52 although its use is not
commonplace.
There are numerous other pleurodesis agents with potential
efﬁcacy. Iodopovidone is widely available in India with one
small RCT demonstrating equivalent success rates to talc.55 The
case for widespread use of acromycin, gentamycin or quinacrine
via chest drains, and silver nitrate or diluted ﬁbrin glue
post-VATS is still to be made.
These results are consistent with recent network meta-analysis
of pleurodesis for malignant pleural effusions, which found that
talc poudrage was highly effective, followed by talc slurry, mepa-
crine, iodine, bleomycin and doxycycline, although this is
clearly a different patient population.61
The indication for pleurodesis in the vast majority of studies
was ongoing air leak or recurrence prevention at second occur-
rence as per guideline recommendation. However, one study
assessed early surgical intervention at ﬁrst occurrence.27 This
group was controversially managed without aspiration or chest
tube drainage, undergoing VATS with bleb resection and talc
poudrage pleurodesis within 12 hours of ﬁrst presentation.
While none of these patients had a subsequent recurrence, it is
likely that a signiﬁcant proportion were unnecessarily operated
upon as many may have resolved with conservative management
and not recurred.
There are a number of limitations to this systematic review.
First, our review is limited by the quality of the available data.
Although we identiﬁed a few well-conducted RCTs, the majority
of identiﬁed studies were observational, many of which were
non-comparative. Many included studies were also retrospect-
ive, with a high risk of reporting bias. Thirteen papers published
pre-1995 in foreign (non-English) language and not available in
print were not included. Indications for pleurodesis varied
across the studies including those solely assessing patients at ﬁrst
occurrence, those with recurrent pneumothorax or air leak
patients, and those with ongoing air leak only. Size of pneumo-
thorax at presentation and details of previous treatment were
not always provided. There was variation both within and across
surgical studies as to the speciﬁc co-incident procedure being
undertaken (alongside chemical pleurodesis). The exact proced-
ure was often determined on visual inspection of the lung (eg,
bleb/bullae resection or electrocoagulation only performed if
visible blebs and bullae seen) but results usually only reported as
overall recurrence rates. This results in signiﬁcant clinical het-
erogeneity in the published data, and therefore interpretation of
results across study types should be guarded.
CONCLUSION
This comprehensive systematic review of the literature demon-
strates that numerous agents have been used for chemical pleur-
odesis for recurrence prevention in SP. Chemical pleurodesis
alongside surgical treatment or via thoracoscopy appears most
effective in preventing recurrence, but is not suitable for all
patients. Evidence for relative success rates between agents is
limited by the small number of randomised and prospective com-
parative trials. Well-controlled and conducted RCTs are now
required using a number of candidate agents to assess optimal
management in SP recurrence prevention and treatment.
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